Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron in Korean Men with Overactive Bladder
NCT02361502Phase 4Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Feb 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in overactive bladder (OAB) comparing Mirabegron with Placebo (2 arms). Primary endpoint: Change in mean number of micturitions per 24 hours at 12 weeks. Status: unknown.
02
Drugs
mirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02361502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02361502.